Figure 3
Major histocompatibility complex tetramer analysis in patients receiving tremelimumab. Bar graphs represent percentages of CD8+ T cells specific for (A) negative control epitope and (B) MART126–35 in samples from all patients and available time points in the tetramer analyses. MART1 = Melanoma-associated antigen recognized by T cells; EOS = End of study.